Dr Godfrey Grech University of Malta

Slides:



Advertisements
Similar presentations
1. 2 Key Applications of Genetic and Genomic Testing (slide 1 of 2) Diagnosis of Disease: Whereby genetic or genomic tests are used to screen a patient.
Advertisements

Tumor Markers Lecture one By Dr. Reem Sallam. Objectives  To briefly introduce cancers, their incidence, some common terms, and staging system.  To.
Healthy Purdue Stacey L. Mobley, PhD, RD, CNSD Assistant Professor Department of Foods and Nutrition A Platform for Research in Disease Prevention and.
Departments - Surgery - Gerontology and Geriatrics Department of SurgeryDepartment of Gerontology & Geriatrics Prof. dr. C.J.H. van de VeldeProf. dr. R.G.J.
MiRNA-drug resistance mechanisms Summary Hypothesis: The interplay between miRNAs, signaling pathways and epigenetic and genetic alterations are responsible.
16 November 2004Biomedical Imaging BMEN Biomedical Imaging of the Future Alvin T. Yeh Department of Biomedical Engineering Texas A&M University.
1 Biomedical Sciences Public and Environmental Health Regenerative Medicine Translational Research.
Strategic Center for Clinical Cancer Research Clinical Cancer Research using Emerging Advanced Technologies for Health Title Slide.
Tumor Markers Lecture one By Dr. Waheed Al-Harizi.
Introduction of Cancer Molecular Epidemiology Zuo-Feng Zhang, MD, PhD University of California Los Angeles.
Clinical Perspective. Screening/Prevention Who is at risk for what type Decision to Intervene: Risk Assessment normal Evidence of Disease Disability Death.
Genetic Testing in Genomic Medicine Gail H. Vance M.D. Professor, Department of Medical & Molecular Genetics Indiana University School of Medicine.
Date Name Speaker Institute / University. Raman4Clinics – Raman-Based Applications for Clinical Diagnostics Based on Raman Spectroscopy and to overcome.
The NIH Roadmap for Medical Research
Pharmacogenomics and personalized medicines Jean-Marie Boeynaems
Paola CASTAGNOLI Maria FOTI Microarrays. Applicazioni nella genomica funzionale e nel genotyping DIPARTIMENTO DI BIOTECNOLOGIE E BIOSCIENZE.
Luděk Bláha, PřF MU, RECETOX BIOMARKERS AND TOXICITY MECHANISMS 13 – BIOMARKERS Summary and final notes.
Molecular Biomarkers in Radiotherapy of Cervical Cancer A collaboration project between Department of Gynecologic Oncology and Department of Radiation.
BIOLOGIC MARKERS IN OCCUPATIONAL AND ENVIRONMENTAL MEDICINE By: Dr Chavoshi.
©2009 RALPH SNYDERMAN 1 Personalized Health Care: The Foundation of Rational Health Reform Ralph Snyderman, MD Chancellor Emeritus, Duke University James.
The Need for Organ Site Specific Cancer Research John T Isaacs Chemical Therapeutic Program Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
Bioinformatics and medicine: Are we meeting the challenge?
Where to focus? Horizon 2020 'Health, demographic change and wellbeing' Open Info Day -Horizon 2020 'Health, demographic change and wellbeing' Brussels,
Alzheimer’s Society, UK Our research programme
Clinical Pharmacy Part 2
Precision Medicine A New Initiative. The Concept of Precision Medicine (PM) The prevention and treatment strategies that take individual variability into.
Integrated Biomedical Information for Better Health Workprogramme Call 4 IST Conference- Networking Session.
Biobanking and data sharing for the progress of collaboration on GSD International meeting Glycogen Storage Diseases associations Milan October 2 nd 2010.
The Value of Tissue Banks to Drug and Dx Developers Barbara L. Handelin, Ph.D. Conflicts of Interest, Privacy/Confidentiality, and Tissue Repositories:
OMICS International welcomes submissions that are original and technically so as to serve both the developing world and developed countries in the best.
Developing medicines for the future and why it is challenging Angela Milne.
The Use of Predictive Biomarkers in Clinical Trial Design Richard Simon, D.Sc. Chief, Biometric Research Branch National Cancer Institute
Bringing Genomics Home Your DNA: A Blueprint for Better Health Dr. Brad Popovich Chief Scientific Officer Genome British Columbia March 24, 2015 / Vancouver,
Cancers of the Digestive System November 19, 2007 NCDD Meeting Chair: John M. Carethers, MD Vice Chair: Robert Sandler, MD, MPH.
Inflammatory Bowel Diseases November 19, 2007 NCDD Meeting Chair: Daniel K. Podolsky, MD Vice Chair: Eugene B. Chang, MD.
Full Proposal for the German Cancer Aid Priority Program 'Translational Oncology' (2st call) 2015 Lead Applicants: Prof. Dr. med. Magnus von Knebel Doeberitz.
INTERPRETING GENETIC MUTATIONAL DATA FOR CLINICAL ONCOLOGY Ben Ho Park, M.D., Ph.D. Associate Professor of Oncology Johns Hopkins University May 2014.
Molecular Biomarkers & Targets an overview Michael Messenger NIHR Diagnostic Evidence Co-Operative & Leeds Cancer Research UK Centre.
Different microarray applications Rita Holdhus Introduction to microarrays September 2010 microarray.no Aim of lecture: To get some basic knowledge about.
I farmaci innovativi in una prospettiva europea Giuseppe M.C. Rosano, MD, PhD Cardiovascular and Cell Sciences Research Institute, St George's University.
Doug Brutlag 2011 The impact of genomics on the future of medicine and health Muhammad Faisal 2015-Arid-3638 PhD(scholar) Biochemistry.
European Patients’ Academy on Therapeutic Innovation Challenges in Personalised Medicine.
Moiz Bakhiet, MD, PhD, Professor and Chairman
San Antonio Breast Cancer Symposium – December 6-10, 2016
Emerging Genomic Technologies: Extending the Application of Genomics to Prediction, Diagnosis, Monitoring, and Early Detection Luis A. Diaz, M.D. Johns.
New research areas in personalised medicines
TITIN ANDRI WIHASTUTI SCHOOL OF NURSING FACULTY OF MEDICINE
Biomarkers.
OMICS Journals are welcoming Submissions
Profiles of gene expression & diagnosis/prognosis of cancer
Biomedical Data Science for Precision Medicine
GENETIC BIOMARKERS.
Pharmacogenomics: towards personalized medicine
Stephen Joseph Galli, MD  Journal of Allergy and Clinical Immunology 
FP6 Priority 1, Life Sciences Genomics and Biotechnology for Health
Clinical evaluation of UHC for cancer
Gene expression.
Biomedical Therapies Foundation Standard 1: Academic Foundation
Techniques for measuring minimal residual disease in leukemia
OMICS Journals are welcoming Submissions
Human Health and Disease
Figure 1 Metabolic profiling as a tool for studying rheumatic diseases
Transcriptional Signature of Histone Deacetylases in Breast cancer
The Genetic Basis for Cancer Treatment Decisions
FP6 Priority 1, Life Sciences Genomics and Biotechnology for Health
PROSTATE CANCER CIRCULATING BIOMARKER CONSENSUS STATEMENT QUESTIONS
12th – 13th November GRANADA
IMI – an opportunity to implement research for patients and with patients Catherine Brett European Parliament Interest Group on Allergy and Asthma
LiSyM- Pillar II Chronic liver disease progression
How Is Precision Medicine Transforming The Health Care Industry?
Presentation transcript:

Application of Molecular Medicine towards personalised treatment in Oncology. Dr Godfrey Grech University of Malta Editor of book (July 2015) entitled “ Preventive and Predictive Genetics: Towards Personalised Medicine” http://www.springer.com/us/book/9783319153438

Application of Molecular Medicine towards personalised treatment in Oncology. Current health care Desirable health care predictive diagnosis & prevention appearance of symptoms Life quality Life quality appearance of symptoms therapy Development of pathologies, years Development of pathologies, years The Paradigm Shift from Reactive to Predictive, Preventive and Personalized Medicine

Application of Molecular Medicine Oncology Guidelines Cost-benefit analysis Health Care model Organisation Implementation Health Care Providers Preventive, Predictive, Personalised Medicine (PPPM) Provision of Services Public Health, Cancer Biology, biomarker discovery, therapeutic options, availability of technologies.

Keywords: Predictive preventive personalized medicine; Risk assessment; Expert recommendation; Standardization; Individual profile; Disease modeling; Multimodal diagnostics; Screening; Biomarker; Biobank

Application of Molecular Medicine Oncology PPPM provides radical shift in cancer treatment “Ensure that every person with a long-term condition or disability has a personalised care plan supporting them to develop the knowledge, skills and confidence to manage their own health”…”develop and implement a best practice standard defining good, personalised, digital care plans in order to support GPs and health professionals”

Application of Molecular Medicine Oncology Risk factors Predisposing to cancer progression Viruses and cancer risk Gut microbiota, inflammation and cancer Cancer predisposing syndromes

Application of Molecular Medicine Oncology Understanding cancer at a molecular level Genetic level Genetic mutations eg PPP1R3 Aberrant copy number Microsatellite instability Promoter hypermethylation mRNA and miRNA Protein Level Dysfunction in enzyme activity Mislocalisation of proteins Alternative splicing Metabolites

Breast cancer was comprised of 5 subtypes Omic Prognosis Prediction: A “Classic” Question First Explored in Breast Cancer Breast cancer was comprised of 5 subtypes Each of which is characterized by some unique and some common genes Sorlie et al. PNAS Sept 11, 2001

These Subtypes Have Different Prognoses Sorlie et al. PNAS Sept 11, 2001 Not properly validated for 6 years, until Rob Tibshirani’s group did a 600-patient validation study. Kapp et al. BMC Genomics, 2007

Application of Molecular Medicine Oncology Preventive and Predictive biomarkers: towards Personalised Medicine Treatment modalities and adjustment Efficacy and toxicity Pharmacogenetics to predict treatment outcome

Application of Molecular Medicine Oncology

Application of Molecular Medicine Oncology Current technologies: a brighter future Single analysis for multi-cancer screening using metabolic information in blood Dynamic analysis for monitoring therapy response using circulating cell-free tumor DNA Imaging cancer for screening, diagnosis, staging and therapy response indicators Access to archival material for faster validation of results Nanotechnologies – the challenge for advanced diagnosis, treatment and prevention

Innovative Technologies Tools Current Technologies Ideas Conferences & Networking Applied Commercialisation Innovative Technologies ….The technologies are ready … & cooperations are welcome….

Innovative Technologies Tools Current Technologies Ideas Conferences & Networking Applied Commercialisation QuantiGene® Assays ‘Direct-from-sample’ miRNA, RNA and DNA quantitation Innovative Technologies Gene expression quantitation directly from the source Branched DNA - Signal Amplification Assay No miRNA, RNA and DNA isolation No reverse transcription No PCR amplification ANY SAMPLE cells, tissues, viruses, bacteria, FFPE, blood, saliva, semen, etc.

Innovative Technologies Tools Current Technologies Ideas Conferences & Networking Applied Commercialisation Innovative Technologies ….The technologies are ready … & cooperations are welcome….

Application of Molecular Medicine Oncology Tools Current Technologies Ideas Conferences & Networking Applied Translation to the Clinic Day 2 November 03, 2015 Track 4: Biomedical and Translational Medicine Research 15:35-15:55 Molecular classification of breast cancer using a multiplex assay

Application of Molecular Medicine Oncology Tools Current Technologies Ideas Conferences & Networking Applied Translation to Clinic Application of Molecular Medicine Oncology Translation to Clinic Improved techniques offering better results with increased sensitivity Novel biomarkers to classify patient subtypes Novel protein targets Pharmacogenetic markers

A World of Opportunities … success stories Tools Current Technologies Ideas Conferences & Networking Applied Translation to Clinic Outcomes

Application of Molecular Medicine Oncology Know your population Guidelines Cost-benefit analysis Health Care model Proper design of clinical trials Organisation Implementation Well-defined outcome measures eTools (harmonised data sets) Health Care Providers Preventive, Predictive, Personalised Medicine (PPPM) Provision of Services Rapid, specific and sensitive methods Screening Programmes eHealth Records (data sharing) Imaging, genetic and novel technology Knowledge Transfer Structured Education Defined Competencies Cancer Biology, biomarker discovery, therapeutic options, availability of technologies, multidisciplinary approach.

Application of Molecular Medicine Oncology Guidelines Cost-benefit analysis Health Care model Organisation Implementation Know your population / cohort Implement preventive measures Reduce cancer risk Earlier detection Better patient management Better Quality of Life Health Care Providers Provision of Services Preventive, Predictive, Personalised Medicine (PPPM) Outcomes Cancer Biology, biomarker discovery, therapeutic options, availability of technologies, multidisciplinary approach.

Application of Molecular Medicine towards personalised treatment in Oncology. Current health care Desirable health care predictive diagnosis & prevention appearance of symptoms Life quality Life quality appearance of symptoms therapy Development of pathologies, years Development of pathologies, years The Paradigm Shift from Reactive to Predictive, Preventive and Personalized Medicine

Application of Molecular Medicine Oncology Guidelines Cost-benefit analysis Health Care model Prioritise actionable risk factors Promote healthy diets Measure pre-disposition markers Provide risk assessment formulate health care economic studies prepare guidelines to monitor risks define harmonised health care strategies develop guidelines to implement effective screening and diagnostic algorithms expand and improve image guided treatments, adjustment of treatment modalities based on pre-defined algorithms Longitudinal actions provision of relevant education programs technological innovation medical research followed by evidence-based implementation to the clinic. Organisation Implementation Health Care Providers Provision of Services Preventive, Predictive, Personalised Medicine (PPPM) Recommendations Cancer Biology, biomarker discovery, therapeutic options, availability of technologies, multidisciplinary approach.

A World of Opportunities with New Innovations in Bio Industry Biomedical and Translational Medicine Research World Bio Summit and Expo Dubai on 02-04 November Dr Godfrey Grech Thank You to the organisers Omics International and Middle East Molecular Biology Society Thank You to the scientific committee Thank you for listening